NMLSF (Restart Life Sciences) EBITDA Margin % : 0.00% (As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Restart Life Sciences EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Restart Life Sciences's EBITDA for the three months ended in Sep. 2024 was $-0.09 Mil. Restart Life Sciences's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, Restart Life Sciences's EBITDA margin for the quarter that ended in Sep. 2024 was 0.00%.

Restart Life Sciences EBITDA Margin % Historical Data

The historical data trend for Restart Life Sciences's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Restart Life Sciences EBITDA Margin % Chart

Restart Life Sciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBITDA Margin %

Get a 7-Day Free Trial

-18,400.00

-15,566.67

Restart Life Sciences Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Mar24	Jun24	Sep24
EBITDA Margin %	Get a 7-Day Free Trial															-	-666.67	-	-	-

Competitive Comparison of Restart Life Sciences's EBITDA Margin %

For the Biotechnology subindustry, Restart Life Sciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Restart Life Sciences's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Restart Life Sciences's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Restart Life Sciences's EBITDA Margin % falls into.

Restart Life Sciences EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Restart Life Sciences's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-1.423	/	0
	=	%

Restart Life Sciences's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-0.091	/	0
	=	%

Restart Life Sciences (OTCPK:NMLSF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Restart Life Sciences EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Restart Life Sciences's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Restart Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Restart Life Sciences Corp (OTCPK:NMLSF) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

HN3:Germany HN3:Germany HEAL.X:Canada

Address

700-838 West Hastings Street, Vancouver, BC, CAN, V6C 0A6

Website

https://www.novamentis.ca

Restart Life Sciences Corp is a Canadian life sciences company dedicated to addressing today's health challenges with wellness solutions. It is focus is on creating health foods that address the needs of this community. Its Flagship developments includes Autism Spectrum, Health-Related Foods, Psilocybin Clinical Trial for Fragile X Syndrome, Orphan Drug Designation (FDA and EMA).